Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp.

ctDNA dynamics were measured by droplet digital PCR in 69 people with metastatic uveal melanoma treated with tebentafusp.

Nature CommunicationsPubMed 39402032DOI 10.1038/s41467-024-53145-0